ENTITY
Biocytogen Pharmaceuticals

Biocytogen Pharmaceuticals (2315 HK)

74
Analysis
Industrials • China
Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs and preclinical research services. It offers gene-editing services, preclinical pharmacology and efficacy evaluation, and sells animal models under its BioMice™ sub-brand. The company also utilizes its proprietary RenMice® platforms for fully human antibody discovery. It was founded in 2008 and is headquartered in Beijing, China.
more
bullish•WuXi XDC
•10 Jan 2025 19:26

Wuxi XDC Placement - A Repeat of Biologics Placement Saga, Last Deal Did Well

WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK). It has sold earlier in Nov 24 as well.

Logo
806 Views
Share
bearish•WuXi XDC
•08 May 2024 07:00

Wuxi XDC Lock-Up - US$300m Lockup Expiry Could See Some Selling Owing to the Regulatory Overhang

WuXi XDC Cayman (2268 HK) was listed in Hong Kong on 17th Nov 2023 after raising US$470m. Its six-month lockup will expire on 16th May 2024.

Logo
730 Views
Share
bullish•WuXi XDC
•16 Nov 2023 08:09

WuXi XDC Cayman IPO Trading - Strong Subscription Rates Heading into Listing

WuXi XDC Cayman (1877628D HK) raised US$470m in its Hong Kong IPO. In our previous notes, we looked at the company’s past performance and...

Logo
665 Views
Share
bullish•WuXi XDC
•07 Nov 2023 11:39

WuXi XDC Cayman IPO - Decent Upside from IPO Range, Bulk of the Deal Taken up by Marquee Investors

WuXi XDC Cayman (1877628D HK) is looking to raise US$470m in its Hong Kong IPO. In this note, we will look at the deal dynamics and share our final...

Logo
852 Views
Share
bullish•WuXi XDC
•06 Nov 2023 14:19

WuXi XDC Cayman Pre-IPO - BULL/BEAR Scenario Considerations for Valuations

WuXi XDC Cayman (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we share our updated thoughts on...

Logo
628 Views
Share
x